Phathom Pharmaceuticals, Inc.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $175.1M
- Net income
- -$221.2M
- Total assets
- $259.1M
- Market cap
- $807.9M
- Gross margin
- 87.1%
- Operating margin
- -91.4%
- Net margin
- -126.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $175.1M
- Cost of revenue
- $22.6M
- Gross profit
- $152.5M
- Operating expenses
- $312.5M
- Operating income
- -$160.0M
- Income tax
- $0
- Net income
- -$221.2M
- EPS (basic)
- $-3.03
- EPS (diluted)
- $-3.03
Balance sheet
- Total assets
- $259.1M
- Current assets
- $229.0M
- Total liabilities
- $697.3M
- Current liabilities
- $132.0M
- Shareholders’ equity
- -$438.2M
Cash flow
- Operating cash flow
- -$166.8M
- Investing cash flow
- -$229.0K
- Financing cash flow
- -$288.0K
- Net cash flow
- -$167.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $807.9M
- EPS (diluted)
- $-3.03
- Shares outstanding
- 82.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 25, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $221.2M in FY2025.
- Gross margin of 87.1%, net margin -126.3%.
- Trading 46% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Phathom Pharmaceuticals, Inc..
Write a review
News about Phathom Pharmaceuticals, Inc.
News & sentiment via Polygon.io
